TAK - EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze
2024-01-29 17:25:44 ET
More on Halozyme Therapeutics, Takeda Pharmaceutical, etc.
- Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
- Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway
- Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript
- Takeda wins EU approval for Hyqvia CIDP indication
- New ADHD drugs could pay off for pharmaceutical companies